Drug used in transplants could slow rare Muscle-Wasting disease
NCT ID NCT04789070
Summary
This study is testing whether sirolimus, a medication used in organ transplants, can slow down or stop the progression of inclusion body myositis (IBM), a rare muscle-wasting disease. It will involve 140 adults with IBM who will take the drug or a placebo for 84 weeks to see if it helps them maintain daily functions like walking, dressing, and swallowing. The goal is to confirm earlier promising results and see if this treatment can help patients stay independent longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INCLUSION BODY MYOSITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Health
Melbourne, Victoria, Australia
-
Concord Repatriation Hospital
Sydney, New South Wales, Australia
-
Johns Hopkins University
Baltimore, Maryland, 21218, United States
-
Leiden University Medical Center
Leiden, Netherlands
-
Perron Institute
Perth, Washington, Australia
-
Royal Adelaide Hospital
Adelaide, South Australia, Australia
-
Royal Brisbane and Women's Hospital
Brisbane, Queensland, Australia
-
Royal Northshore Hospital
Sydney, New South Wales, Australia
-
St Vincent's Hospital
Melbourne, Victoria, Australia
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
Conditions
Explore the condition pages connected to this study.